Experimental combo aims to reboot immune system against Hard-to-Treat cancers
NCT ID NCT02961101
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymphoma, lung, breast, and liver cancers. The goal is to see if these combinations are safe and effective at shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-PD-1 antibody (a drug that helps the immune system attack cancer) and low-dose decitabine (a chemotherapy-like drug)
- What this could lead to
- If successful, this could provide a new treatment option for patients with several types of cancer that have not responded to standard therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. Side effects from the combination therapy are possible and are being closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Could a simple scan and blood test outsmart liver cancer?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts